Key result
Metrnl plays a significant role in the pathogenesis of various cardiomyopathies, offering potential new insights for the treatment of these diseases.
Why the study?
Cardiomyopathies have limited treatment options targeting molecular dysregulations, while emerging evidence suggests the cardiokine Metrnl plays a role in their pathogenesis.
This review highlights the emerging role of Metrnl in the pathogenesis of cardiomyopathies, suggesting its potential as a therapeutic target.
Metrnl's role in cardiomyopathies is hypothesis-generating; leaves open whether targeting it improves outcomes in clinical trials.
Cardiomyopathies, a diverse group of diseases affecting the heart muscle, continue to pose significant clinical challenges due to their complex aetiologies and limited treatment options targeting underlying genetic and molecular dysregulations. Emerging evidence indicates that Metrnl, a myokine, adipokine and cardiokine, plays a significant role in the pathogenesis of various cardiomyopathies. Therefore, the objective of this review is to examine the role and mechanism of Metrnl in various cardiomyopathies, with the expectation of providing new insights for the treatment of these diseases.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) conducted a review in Cardiomyopathies. Metrnl was evaluated. Metrnl plays a significant role in the pathogenesis of various cardiomyopathies, offering potential new insights for the treatment of these diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: